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Abstract
Background: The production of recombinant monoclonal antibodies in mammalian cell culture is of high priority
in research and medical fields. A critical step in this process is the isolation of the antigen-binding domain
sequences of antibodies possessing the desired properties. Many different techniques have been described to
achieve this goal, but all have shortcomings; most techniques have problems with robustness, are time-consuming
and costly, or have complications in the transfer from isolation to production phase. Here, we report a novel
HybriFree technology for the development of monoclonal antibodies from different species that is robust, rapid,
inexpensive and flexible and can be used for the subsequent production of antibodies in mammalian cell factories.
Results: HybriFree technology is illustrated herein via detailed examples of isolating mouse, rabbit and chicken
monoclonal antibody sequences from immunized animals. Starting from crude spleen samples, antigen capturing
of specific B-cells is performed initially. cDNA of antibody variable domains is amplified from the captured cells and
used a source material for simple and rapid restriction/ligation free cloning of expression vector library in order to
produce scFv-Fc or intact IgG antibodies. The vectors can be directly used for screening purposes as well as for the
subsequent production of the developed monoclonal antibodies in mammalian cell culture. The antibodies isolated
by the method have been shown to be functional in different immunoassays, including ELISA, immunofluorescence
and Western blot. In addition, we demonstrate that by using a modified method including a negative selection
step, we can isolate specific antibodies targeting the desired epitope and eliminate antibodies directed to
undesired off-targets.
Conclusions: HybriFree can be used for the reliable development of monoclonal antibodies and their subsequent
production in mammalian cells. This simple protocol requires neither the culturing of B-cells nor single-cell
manipulations, and only standard molecular biology laboratory equipment is needed. In principle, the method is
applicable to any species for which antibody cDNA sequence information is available.
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Background
Monoclonal antibodies (MAbs) are made by identical
immune cells and target one particular epitope by mono-
valent or monospecific affinity. The high affinity and
selective binding of MAbs to epitopes in target antigens
makes them highly potent tools for use in biochemis-
try, molecular biology and medicine. The first working
method described for the isolation of monoclonal
antibodies was hybridoma technology, based on forming
hybrid cell lines (hybridomas) by fusing an antibody-
producing B-cell with a myeloma cell [1]. The antibodies
produced by a particular hybridoma clone share the same
specificity. Thus, individual clones can be screened for the
production of an antibody with the desired affinity. How-
ever, hybridoma technology has shortcomings: it takes a
relatively long time (on the order of months) and has not
been widely applied to organisms other than mice. More-
over, antibody sequence information is unavailable by this
method. Thus, when a hybridoma-screened antibody is
selected for further development (e.g., as a therapeutic
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product), the cDNA encoding the variable domains of the
heavy (VH) and light chain (VL) must be isolated from
the hybridoma cells. This step is required for the recom-
binant production of the final MAb product, as well as for
improvements such as humanization, isotype conversion,
and affinity maturation.
Alternatively, recombinant antibody isolation technolo-
gies usually do not include a hybrid cell line step, but
instead clone the VH and VL domain sequences from the
antibody-expressing source cells (e.g., B-cells from spleen,
bone marrow or blood). Commonly, VH and VL cDNA is
amplified by RT-PCR using mRNA isolated from the cells.
By combinatorial strategies, a large repertoire of different
VH and VL sequences are amplified from a population of
cells (e.g., millions of B-cells isolated from an immunized
animal). Thereafter, the amplified products are used for
the construction of combinatorial libraries by the random
pairing of the VH and VL domains. Thus, combinatorial
strategies must involve a screening step for the identifi-
cation of antibodies (VH and VL combinations) with the
desired properties from large libraries. These screening
methods involve in vitro antibody display techniques
including phage display [2, 3], ribosome display [4], and in
vivo display platforms such as bacterial, yeast, and mam-
malian cell-surface displays [5]. Mammalian cell display
has a number of advantageous features, especially for
selecting antibodies for recombinant production [6]. For
example, using mammalian cells for MAb screening mini-
mizes the loss of MAb during downstream production in
mammalian cells, a complication sometimes associated
with MAbs screened in phage, bacterial or even yeast dis-
play systems. Instead, performing antibody selection in
mammalian cells ensures that the selected antibody is syn-
thesized, modified, assembled and secreted through the
same cellular pathways employed in the production phase.
Recombinant methods also include non-combinatorial
strategies that are based on retrieving antibody sequen-
ces from a single B-cell or the clonally expanded pro-
geny of a single cell. Using this technique, the original
heavy and light chain pairs are maintained together
during the isolation process (for a review, see ref. [7]).
This is achieved by the amplification of rearranged VH
and VL region cDNAs from one particular B-cell by
technically challenging single-cell RT-PCR methods [8].
Furthermore, isolated single B-cells can be amplified in
cell culture. These methods include the immortalization
of differentiated B-cells by the Epstein-Barr virus (EBV),
retroviral oncogenes, or TLR ligands (reviewed in ref.
[7]); by cultivation under specific conditions with irradi-
ated thymoma cells [9, 10]; or by IL4 treatment and
CD40 triggering [11]. These techniques were devel-
oped to facilitate and increase the efficiency of non-
combinatorial strategies (e.g., the enrichment of source
B-cells that express antibodies with the desired affinity).
However, all non-combinatorial methods involve either
complicated single-cell manipulations and/or the estab-
lishment of sterile primary cell cultures from unsterile bio-
logical materials, as well as specialized equipment and/or
expensive supplements. Any MAb development strategy
can potentially include negative or “subtractive” screening
steps to eliminate the recovery of antibodies recognizing
the target antigen but also some non-desired off-target(s).
This is especially useful for the development of very spe-
cific MAbs that can bind to specific protein modifications
[12, 13] or recognize a specific member of a protein family
with common domains, motifs and/or structures [14].
Here, we describe the novel HybriFree technology,
which combines elements of both combinatorial and
non-combinatorial strategies and involves a screening
step performed using mammalian cells. This method is
universal and is in principle applicable to any species for
which antibody sequence information is sufficient for
designing primers for VH and VL cDNA amplification.
The key property of HybriFree technology is its rapid
and robust workflow: it takes approximately 10 days to
go from source material collection to obtaining expression
vectors for antigen-specific antibodies, together with se-
quence information regarding their VH-VL combinations.
The method does not require the establishment of sterile
B-cell cultures, single cell manipulations or specialized
materials. Additionally, we have supplemented the method
with an optional negative selection step to eliminate the




Six- to eight-month-old Hy-Line chickens were immu-
nized by four (weeks 0, 2, 4 and 18) intramuscular (im)
injections of 0.5 mg protein antigen in complete (initial
immunization) or incomplete (subsequent immunizations)
Freund adjuvant. An antigen boost was given intra-
venously (iv) 2 weeks after the final injection as 0.1 mg
protein in PBS.
Mice
Four- to six-week-old female BALB/c mice were initially
immunized intraperitionally (ip) with ~50 μg of protein
antigen in complete Freund adjuvant (week 0), followed
with 5 ip administrations (weeks 3, 7, 16, and 2 times in
week 17) with the same amount of antigen in PBS.
Rabbits
Approximately 5-month-old New Zealand rabbits were
initially immunized by 2 subscapular injections (one in
each side of the body). The protein antigen, or virus-like
particles (VLPs), was administered 4–5 times in amounts
of 0.1-0.4 mg in complete Freund (first immunization
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only) adjuvant or in incomplete Freund adjuvant. The
response was boosted by an intravenous injection of
0.1 mg protein antigen.
All of the procedures performed using animals were in
accordance with the European Union directive 86/609/
EEC and were approved by the Estonian National Board
of Animal Experiments (No. 115, 07.09.2012; No. 87,
28.08.2007).
Collection and preparation of spleen cells
After the confirmation of antigen-specific antibody
response in egg yolk preparations (chickens; IgY) or in
blood serum (mice and rabbits; IgG), spleens were col-
lected 2–4 days after final immunization (i.e., the final
boost). The animals were anesthetized, and cardiac
puncture was used to collect blood. The spleen was
removed and stored on ice until treatment (within one
hour). For the preparation of cell homogenate, the spleen
was homogenized in ice-cold PBS using a 40 μm cell dis-
sociation sieve. The material was collected in a 50 ml cell
culture tube and precipitated by centrifugation at 300 × g
for 5 min at 4 °C. The cells were re-suspended in 50 ml of
ice-cold PBS and centrifuged again. Finally, the precipi-
tated cells were suspended in 5 ml ice-cold freezing
medium (heat inactivated fetal bovine serum + 10 %
DMSO), distributed into cryovials (1 ml per tube), and
slowly frozen to −80 °C. For longer storage, the tubes were
transferred into liquid nitrogen after 4–5 days.
Preparation of the cells for capturing: The frozen
spleen cell suspension was thawed and transferred into
10 ml of RPMI1640 cell culture medium at ambient
temperature. The cells were collected by centrifugation
(200–300 × g, 5 min, room temperature), re-suspended
in 10 ml of RPMI1640 supplemented with penicillin/
streptomycin and 10 % of heat inactivated fetal bovine
serum (rabbit or mouse splenocytes) or chicken serum
(chicken splenocytes). The cells were seeded into a
100 mm cell culture dish and incubated ~1 h at 37 °C in
a 5-8 % CO2 atmosphere. Then, free-floating cells were
carefully collected, and the viability of the cells was evalu-
ated using trypan blue exclusion. The cells were sedimen-
ted by centrifugation and re-suspended in the capture
medium (RPMI1640 supplemented with 0.5 % BSA and
0.1 % NaN3). The chicken splenocyte preparations con-
tained a high amount of erythrocytes; therefore, an add-
itional Optiprep™ (60 % iodixanol, Axis-Shield PoC AS,
Norway) gradient purification step was included by the
sedimentation of lymphocytes along a density barrier [15]
before re-suspension in the capture medium.
Capturing: MaxiSorp™ surface 96-wells (Thermo Fisher
Scientific, US) were coated with the antigen (20 μg/ml in
PBS, 4 °C, overnight) and blocked for 1–2 h with 2 %
BSA in PBS. One hundred microliters of cell suspension
containing 2 x 104 live cells in capture medium were
loaded into a single well. The plate was centrifuged
(200 × g, 5 min) and incubated for 45–60 min. The
medium was discarded, and loosely attached cells were
removed by washing 4–5 times with PBS, each time pip-
etting gently triturating (3–4 times) at the edge of the
well. Finally, the plastic-bound cells were lysed in the
wells using 200 μl of TriReagent® (Molecular Research
Center, US) and 1–2 μg of yeast tRNA (Life Technolo-
gies, US) carrier added to each well. Total lysate of the
human cell line U2OS was used as a carrier rather than
tRNA in some experiments using chicken splenocytes.
RNA isolation and cDNA first-strand synthesis
The total RNA isolation was performed as recom-
mended by the TriReagent® manufacturer. Material from
2 (mouse, rabbit) or 8 (chicken) wells was pooled to-
gether during the isolation. The final RNA samples were
dissolved in 8 μl of nuclease-free water and subjected to
cDNA first-strand synthesis using the SuperScript® III
First-Strand Synthesis System according to the manufac-
turer’s instructions (Life Technologies, US). This prepar-
ation yielded 20 μl of cDNA reaction per sample.
PCR amplification of VH and VL regions
PCR reactions were performed in 50 μl for a total of
35–40 cycles using Phusion Green Hot Start II High-
Fidelity DNA Polymerase (Life Technologies, US) with
pre-optimized conditions for each reaction. The primers
used for the amplification of antibody VH and VL regions
were designed to maximally cover the variability of the
VH and VL sequences. Primer pairs used for the amplifi-
cation of chicken IgY regions were designed based on
published data [16]. The mouse primer cocktails used for
the amplification of VH and VLκ sequences were designed
based on published data [17] as well as V- and J-region
cDNA sequences available in the international Immuno-
GeneTics information system® (IMGT®) web resource [18].
For the construction of scFv fragments, rabbit VH and VL
primer cocktails were designed and prepared using previ-
ously published data [19]. The sequences of the primers
are listed in Additional file 1. The proprietary VH and VL
primers were used for the construction of libraries ex-
pressing intact rabbit IgG molecules were designed using
rabbit sequences stored at IMGT® [20]. For cloning pur-
poses or forming the coding sequence of the flexible linker
(GGGGS)3 between the VH and VL domains, an add-
itional 20–23 nucleotides were added to the 5’ ends of
primers.
Circular Polymerase Extension Cloning and plasmid DNA
isolation
The restriction- and ligation-independent Circular Poly-
merase Extension Cloning (CPEC) method [21] was used
for library construction by the in-frame-directed cloning
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of amplified VH and VL regions into the pQMCF mam-
malian expression plasmid (Icosagen Cell Factory,
Estonia). Briefly, the variable domain PCR products and
linearized/dephosphorylated vector fragment(s) were
separated and purified from a TAE-agarose gel. Approxi-
mately 100 ng of the vector together with inserts (~2
times molar excess of each) were used in the 20 μl CPEC
reaction with Phusion High-Fidelity DNA Polymerase
(Life Technologies, US). Totally 25 cycles of denatur-
ation, annealing and extension were performed accord-
ing to the the polymerase manufacturer’s instructions.
Five microliters from the reaction were used for the
transformation of competent TOP10 F’ or DH5α strain
E. coli cells. Approximately 1/10 of the transformation
mixture was used for the direct inoculation of 2 ml of
selective carbenicillin-containing liquid growth medium,
followed by the extraction of plasmid DNA (i.e., the li-
brary pool) from overnight culture. Another part of the
transformation mixture was plated onto carbenicillin-
containing solid medium to obtain individual clones.
The bacterial clones were amplified in 0,75 ml of liquid
medium, and plasmid DNA mini-preparations were
purified using a Zyppy™-96 Plasmid Miniprep kit (Zymo
Research, US) or a FavorPrep™ 96-Well Plasmid Kit
(Favorgen Biotech Corp., Taiwan) according to the man-
ufacturer’s instructions.
Cells, transfection and sample collection for mammalian
screening
The Chinese hamster ovary (CHO-S from Thermo
Fisher Scientific, US)-derived cell line CHOEBNALT85
(Icosagen Cell Factory, Estonia) was grown in serum-
free chemically defined medium and was used for anti-
body screening. This cell line expresses EBV EBNA1
protein and mouse polyomavirus large T protein and is
specifically designed for the prolonged and high level
production of proteins in association with pQMCF
vectors (USPTO Patent No: 7,790,446). The cells were
transfected using chemical transfection Reagent 007
(Icosagen Cell Factory, Estonia) according to the pub-
lished protocols [22]. One microgram of plasmid DNA
was transfected in 6-well plate format for analyzing
library pools, and approximately 0.2 - 0.5 μg DNA per
sample was used in a high-throughput 96-well plate
transfection for screening individual clones. Seventy-two
hours after transfection, the supernatants were collected
for analysis. When necessary, scFv-Fc or human IgG1
concentrations in the samples were determined using
FastELISA for Human IgG quantification (RD Biotech,
France).
ELISA
The ELISA plates (Nunc™ MaxiSorp™, Thermo Fisher
Scientific, US) were coated at 4 °C overnight with antigen
solution (2–5 μg/ml) or VLP suspension (20 μg/ml) in
PBS, washed with washing solution (PBS containing
0.05 % Tween 20), and incubated 1–2 h with blocking so-
lution (PBS containing 2 % BSA and 0.05 % Tween 20) at
room temperature. After washing twice, the culture super-
natants (diluted in blocking solution, if necessary) were in-
cubated 1–2 h at room temperature. After washing 4
times, a second incubation was performed with goat
anti-human IgG (for scFv-Fc) or anti-rabbit IgG anti-
body conjugated with HRP (LabAs, Estonia). The signals
were developed with TMB VII substrate (Biopanda Diag-
nostics, UK). The reactions were stopped by the addition
of 0.5 M H2SO4, and absorbance values were measured at
450 nm.
Sequence analysis
Protein sequences of identified antibody VH and VL
were analyzed by exhaustive pairwise global alignments
and the progressive assembly of alignments using
Neighbor-Joining phylogeny for similarity determination.
This was done using Clone Manager Professional (Scien-
tific & Educational Software) and BioEdit Sequence
Alignment [23] software. Complementarity determining
regions (CDRs) in VH and VL amino acid sequences
were determined using ref. [16, 18, 20].
Results and Discussion
Description of the HybriFree technology
The overall HybriFree procedure is illustrated in Fig. 1.
Its key steps include: (i) the enrichment of source mater-
ial via capturing antibody producers by exposing them
on the antigen-loaded solid matrix; (ii) the amplification
of VH and VL coding cDNAs; (iii) the construction of a
combinatorial VH-VL library in mammalian expression
plasmid DNA format; and (iv) screening the proper VH-
VL combinations after antibody expression in mamma-
lian cells. Because screening is usually performed by the
transfection of individual DNAs into mammalian cells in
96-well format, hundreds rather than thousands of
clones can be easily screened in a single round. To en-
sure that appropriate VH-VL combinations are discov-
ered from a limited number of clones, it is crucial to
maintain the diversity of the library in a narrow range.
Ideally, the library should include only the VH and VL
regions that are found in the antibodies recognizing the
antigen of interest. Here, this diversity limitation is
achieved by the functional selection of source cells be-
fore the VH and VL regions are isolated. This is ensured
by capturing the source cells on the solid surface (e.g.,
ELISA plate well) coated with the antigen (step 1, upper
left in Fig. 1). The technique is historically referred to as
“lymphocyte panning” (reviewed in ref. [24]), and the
capture is performed via interactions between the sur-
face immunoglobulin (sIg) molecules of the B-cells [25]
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and the immobilized antigen. For example, lymphocyte
panning has been used to establish retained B-cell cultures
that have been used as a source of VH and VL sequences
[26, 27]. Microwell array chip assay or fluorescence-based
methods have also been used for the identification and
isolation of cells secreting antibodies with desired proper-
ties (reviewed in ref. [28]). However, to our knowledge,
this technique is predominantly used for the isolation of
viable antigen-specific cells for hybridoma generation
and/or in vitro culturing. In contrast, by the HybriFree
method, the captured antigen-specific cells are immedi-
ately subjected to lysis, and therefore the viability of the
yielded cells and selecting the conditions suitable for
B-cell culturing do not pose issues. Instead, we have opti-
mized cell capture conditions for HybriFree technology.
The captured source cells are subjected to RNA isola-
tion, cDNA preparation, and the amplification of VH
and VL cDNAs (step 2, upper right in Fig. 1), followed
by the construction of a combinatorial library in a mam-
malian expression vector (step 3, lower left in Fig. 1).
Using high-throughput techniques, the plasmid DNA was
prepared from single bacterial colonies grown in 96-well
plates and transiently transfected into mammalian cells.
Thereafter, antigen-specific antibody production is evalu-
ated for each clone (step 4, lower right in Fig. 1). Finally,
VH and VL cDNAs are sequenced for the selected positive
clones. The whole process takes no more than 10 days.
Additionally, we introduced an optional pre-adsorption
step to avoid the undesired cross-reactivity of the devel-
oped MAbs. In brief, the source cells are treated with an
excess of off-target protein prior to capturing with desired
target antigen. In this way, all binding sites on the cells
that are cross-reactive with undesired off-targets are satu-
rated and cannot bind to the target antigen anymore. In
the following sections, this method is described in detail
with proof-of-principle examples provided regarding the
isolation of MAbs from rabbit, mouse, and chicken. Ap-
plying the pre-adsorption step for increased selectivity is
also illustrated.
Capturing antigen-specific B cells
We have optimized the capturing of antigen-specific B
cells in antigen-coated 96-wells (MaxiSorp™ surface)
using a non-sterile crude suspension of intact spleen cells
from different animals. However, the removal of plastic-
adherent cells (e.g., macrophages) from lymphocytes
during the first incubation step was found to increase the
capture of antigen-specific lymphocytes as previously de-
scribed [29].
We have most carefully optimized the number of
source cells used per single capture reaction. The num-
ber of bound cells must be sufficient for the robust one-
step amplification of the VH and VL regions. Even if the
amplified VH and VL regions correspond to only those
Fig. 1 General workflow of the HybriFree method. The key steps include (STEP 1) the enrichment of source material by capturing cells producing
specific antibodies; (STEP 2) the amplification of VH and VL cDNA; (STEP 3) construction of a combinatorial VH-VL library in scFv-Fc (or IgG) expression
plasmid DNA format; and (STEP 4) screening proper VH-VL combinations after expression of MAbs in mammalian cells
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antibodies that bind to the target antigen, it is necessary
to maintain the diversity of library within limits suitable
for a mammalian screen. To this end, we have found
that 2–6 x 104 mammalian splenocytes and 8–16 x 104
chicken splenocytes per cDNA sample is optimal. We
have determined that to increase the variability of the re-
covered MAbs, setting up more capturing reactions/well
is preferable to increasing the cell number per well. We
also observed that ~45 min capture time in ambient
temperature is sufficient for cells to bind to the antigen,
without being so long that major degradation of cellular
mRNA without de novo synthesis becomes an issue.
The capturing process is illustrated by examples using
chicken immunized with human DNase I protein, mice
immunized with human artemin protein, and rabbit im-
munized with an HPV18 E2 protein domain fused with
GST (GST-HPV18 E2C). The success of antigen-specific
cell capture was first suggested by the agarose gel elec-
trophoresis of the ~400 bp VH and VL amplification
products, as shown in Fig. 2a-c. In lanes marked (+), the
cells were captured by the relevant target antigen. As a
negative control, identical capturing procedures were per-
formed using wells coated with the non-relevant protein
(lanes marked (−) in Fig. 2). Comparing the signal inten-
sities of PCR products between the (+) and (−) lanes in
Fig. 2, it is obvious that for all source animals, the VH and
VL products were amplified much more efficiently from
(+) cells. However, the capture selectivity is somewhat
dependent on the particular target antigen. High back-
ground levels we have sometimes met are probably caused
by the binding of the spleen cells to the target antigen via
mechanisms other than antibody-antigen interaction.
Supplementing the capture medium with 0.1 % NaN3
improved the yields of amplified PCR products, espe-
cially for chicken splenocytes and/or when cell capture
was initially performed at a higher temperature. This is
illustrated in Fig. 2d by VH and VL amplification from
splenocytes collected from chicken immunized with
mouse CD48 protein. The cells were captured on an
antigen-coated surface at 37 °C using RPMI1640 + 0.5 %
BSA or the same medium supplemented with 0.1 % of
NaN3 as the capture medium. The yield of the VH and VL
products was much higher for reactions supplemented
with NaN3. The success of RNA isolation and cDNA syn-
thesis was confirmed by amplification from human β-
actin-spliced mRNA (an equal amount of human cell line
lysate was used in both samples as a carrier in RNA isola-
tion). We speculate that the favorable impact of NaN3
may be caused by the blocking of antibody internalization
and/or mRNA degradation during capture.
ScFv-Fc library construction
Next, VH-VL combinatorial libraries were constructed
from amplified VH and VL regions (shown in Fig. 2) by
the CPEC technique [21]. For rabbit splenocytes, two
PCR reactions (VH1 and VH2) were used for better
coverage of VH cDNA (Fig. 2c). Thus, two separate
cloning reactions were performed by combining the
VH1 product or VH2 product with the VLκ product. As
illustrated in Fig. 3, during the CPEC reaction between
the 3 fragments (vector, VH, VL), pQMCF scFv-Fc
Fig. 2 Amplification of VH and VL cDNA from spleen cells captured
on an antigen-coated surface. cDNA was prepared from cells captured
on the antigen-coated surface (+) and from control wells coated with
BSA (−). a Splenocytes from chicken immunized with human DNase I
protein. b Spleen homogenate from mouse isolated after immunization
with human artemin protein. c Spleen homogenate from rabbit
immunized with GST-E2C fusion protein. d Improvement of the
VH and VL product yield by NaN3. Chicken splenocytes were
captured in capture medium with or without 0.1 % NaN3, as indicated.
Amplification from human β-actin cDNA was performed (209 bp
product from spliced mRNA) as equal amounts of human cell lysate
were used as a carrier during RNA isolation
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vectors were formed via random combination of VH and
VL fragments and in-frame joining of the scFv cDNA 5’
and 3’ ends with mouse immunoglobulin heavy chain se-
cretion leader peptide cDNA and human IgG1 Fc region
cDNA, respectively. The CPEC reaction is performed by
annealing and extending overlapping regions at the ends
of joined DNA fragments. Thus, during the PCR primer
design we added 20–23 nt. sequences from the 3’ end of
leader peptide cDNA and the 5’ end of the Fc region to
the 5’ end of VH and the 3’ end of VL fragment, res-
pectively. Similarly, using overlapping sequences added
during the PCR, coding sequence of a flexible linker
(GGGGS)3 is created between the VH and VL cDNAs.
This enables CPEC to join 3 fragments into the scFv
expression vector (step 3 in Fig. 1) without the addition
of nucleotides between the vector and the insertions.
Library pool samples (a mixture of all library mem-
bers) and single clone DNA minipreparations (using a
convenient high-throughput 96-well method) were pre-
pared from E. coli cells directly transformed with CPEC
reaction product. PCR analysis of bacterial colonies
showed the high efficiency of the cloning, and routinely
>90 % of CPEC clones contained directed VH-VL inser-
tion in the vector (data not shown).
Mammalian cell screening of antigen-specific scFv-Fc
molecules
In the examples provided below, we used the CHO-
derived cell line CHOEBNALT85 for screening. These
cells grow in serum-free chemically defined medium and
ensure high transfection efficiencies in a variety of scales,
including a 96-well high-throughput format. In association
with the pQMCF vector, CHOEBNALT85 cells ensure
relatively high transient production levels of IgG-like
molecules (typically tens of micrograms per milliliter at
72 h time-point using a 2 ml culture scale). Moreover, we
routinely use the same cells for recombinant antibody
production at larger scales. Using the same cells for
screening and production decreases the odds of subse-
quent problems with productivity. However, any mamma-
lian cell line that can be efficiently transfected with
plasmid DNA expression vector is usable for screening by
this method. In the examples described here, the expres-
sion of scFv-Fc was controlled using the Rous sarcoma
virus long terminal repeat promoter.
The efficiency of the antigen-specific MAb reconstruc-
tion from VH and VL combinations was initially ana-
lyzed via the transfection of library pools. The DNA was
transfected into CHOEBNALT85 cells, and 72 h later
the culture supernatants were assessed by ELISA for the
secretion of antigen-recognizing scFv-Fc molecules. This
is illustrated with the pools created by extraction of plas-
mid DNA (from overnight culture of competent E.coli
cells transformed with the CPEC reaction with VH and
VL products from chicken, mouse or rabbit showed in
Fig. 2. As seen in Fig. 4a-c, positive signals qualitatively
different from the controls were observed in all cases,
suggesting the expression of antigen-specific MAbs in
the libraries. As a next step, individual MAbs with spe-
cific binding were identified by screening plasmid DNA
minipreparations derived from single clones. Using the
high-throughput methods, the mini-preparation plasmid
DNA was isolated from individual bacterial clones from
the CPEC and transfected into CHOEBNALT85 cells.
One or two 96-well plates (including appropriate posi-
tive and negative controls) were analyzed per library,
usually 48 or 72 h post-transfection We arbitrarily de-
fined positive signals as ELISA OD readouts at least 2–3
Fig. 3 Generation of scFv-Fc library by CPEC. Amplified VH and VL fragments are cloned in frame into a vector between secretion leader and Fc
region cDNAs using overlapping regions added at the ends of the PCR products. The overlapping sequences added to variable domains formes a
flexible linker (GGGGS)3 between VH and VL. In each of 25 CPEC cycle, the denaturated inserts and vector are hybridized and extended until completing
full circles. The plasmid library is propagated and recovered by transformation into competent E. coli cells
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times over the negative control (empty expression vector
or expressing a non-relevant scFv-Fc). However, espe-
cially in 72 h time-point, the positive signals typically
qualitatively discriminated from the negative samples by
a readouts at least 10 times higher (Fig. 4d). The effi-
ciency of screening (percentage of positive hits) in our
experiments has varied between 7 % and 60 % for differ-
ent antigen and animal combinations. The net results of
efficiency and outcomes of HybriFree experiments in-
volving different animals, library types and antigens are
summarized in Table 1.
High-throughput methods used for the preparation
and transfection of plasmid DNA usually result in some
variability in DNA concentration, and thus also in trans-
fection efficiency. This can lead to differences in scFv-Fc
expression/secretion level, also influenced by the actual
DNA sequence (codon usage) of VH and VL cDNA. Thus,
the differences in signals observed in 96-well screening do
not necessarily reflect differences in the quality or affinity
of the individual MAbs. Therefore, normalization is neces-
sary for a head-to-head comparison of the selected MAbs.
This is illustrated in Fig. 4 using 10 positive MAbs against
human artemin screened from the mouse library. Normal-
ized ELISA curves are shown in Fig. 4e, and the readouts
of the same clones in an initial high-throughput screen
are illustrated in Fig. 4f.
Screening intact IgG molecules
Isolation of antigen-specific VH and VL pairs via scFv-Fc
screening provides enough information for the construc-
tion of expression vectors necessary for the recombinant
production of the IgG antibodies from heavy and light
chains expressed in the cell as separate polypeptides.
However, in this case, cDNA re-synthesis (by PCR or gene
synthesis), changing the expression vector, and additional
cloning steps are necessary. This makes the process cum-
bersome and time-consuming. Thus, we modified our
method by screening the VH and VL combinations so
that intact IgG molecules are initially formed rather
than scFv-Fc antibodies. To this end, the CPEC strat-
egy was modified to enable the directed in-frame joining
of the 4 fragments (VH, VL, promoters/leaders, and vec-
tor). Here, the VH and VL are both exactly joined with
the secretion leader peptide cDNA at the 5’ end and with
constant domain cDNA at the 3’ end. The reaction
creates just natural joining between variable and con-
stant domain in the IgG heavy and light chain, re-
spectively. The final product resulting from the
CPEC reaction is the pQMCF IgG vector, with separ-
ate expression cassettes for the IgG heavy and light
chain, respectively (Fig. 5a). To ensure efficient di-
rected CPEC assembly of 4 DNA fragments, the
overlapping regions at the ends of the fragments
Fig. 4 Exemplary ELISA analyses of constructed scFv-Fc antibody libraries. a-d The graphs represent the ELISA results of serial dilutions of 72 h
time-point supernatants from CHOEBNALT85 cells transfected with 1 μg of HybriFree library pool DNA from the following captured cells: (a)
chicken immunized with human DNase I; (b) mouse immunized with human artemin; and (c) rabbit immunized with GST-E2C protein. The
irrelevant scFv-Fc vector was used as the negative control in each transfection. d ELISA results of single clone screening of the rabbit GST-E2C
library pool shown in panel c. Wells G12 and H12 were transfected with library pool and negative control DNA, respectively. The clones gave
highly positive OD signals≥ 15 times over the negative control are highlighted in red. The clones with the signals 3–10 times higher than the
negative control have orange highlighting. e Normalized artemin ELISA of 10 anti-artemin clones obtained from the immunized mouse (library
pool ELISA results are shown in Fig. 3b). f Absorbance readouts of the same clones used in initial screening
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Table 1 Hit rates (proportion of antigen recognizing clones) achieved from positive library pools in different HybriFree experiments
Source Library Antigen Pos./all (%) Comments
Chicken scFv Persephine 18/118 (15 %) After B-cell capturing as described here, the
screening was done using E. coli based system
GFRα1 71/140 (50 %)
scFv-Fc hDNase 3/43 (7 %)
hNGF 3/23 (13 %)
HPV18 E2 7/93 (8 %) Full-length protein was used for immunization
but the B-cell capturing and screening were
performed using only C-terminal domain (one-third)
Mouse scFv Persephine 19/190 (10 %) After B-cell capturing as described here, the screening
was done using E. coli based system
scFv-Fc Artemin 12/78 (15 %)
hNGF 7/24 (29 %)
Rabbit scFv-Fc hCD48 7/46 (15 %)
HPV18 E2N-GST 13/93 (14 %)
HPV18 E2C-GST 16/188 (9 %) Summarized results obtained from 2 rabbits
mCD48 80/186 (43 %)
Ebola VLP 25/94 (27 %)
Ebola GP 104/234 (44 %) Summarized results obtained from 3 experiments
IgG Ebola GP 11/46 (24 %)
mCD48 55/94 (59 %) see section “Screening natural intact IgG
molecules” for more details
hBDNF 43/125 (34 %)
Fig. 5 Construction and screening of intact IgG molecules. a The pQMCF IgG vector was constructed using single-step CPEC joining of 4 fragments:
VH, VL, promoters/leaders and vector. The antibody heavy and light chains are expressed from the resulting vector as separate proteins that assemble
naturally into IgG molecules secreted from mammalian cells. b. Western blot analysis of rabbit IgG secretion from CHOEBNALT85 cells transfected with
pQMCF IgG library pool DNA constructed from VH and VL regions from a rabbit immunized with mouse CD48 protein. Goat polyclonal antibody
against rabbit IgG heavy chain was used for the detection of free heavy chain in reduced sample conditions (DTT+) and of the assembled IgG
molecule in non-reduced (DTT-) sample. c Mouse CD48 ELISA results obtained using serial dilutions of the same sample of library pool transfection
media as primary antibody. d Distribution of positive and negative clones obtained from the screening of the library pool showed in the panel c. Three
positive and two negative clones selected for sequencing are indicated. e Alignment of VL domain amino acid sequences of the positive and negative
clones. CDR regions are underlined
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were carefully optimized using synonymous replace-
ments in cDNA encoding the leader peptide and constant
region.
The modification in this method is illustrated by the
development of rabbit MAbs against mouse CD48 pro-
tein. VH and VL fragments were created from spleen
cells captured on mouse CD48-coated wells. The cloning
reaction was performed using pQMCF IgG vector
containing rabbit IgG heavy and light (kappa) chain
constant region codon-optimized cDNAs. The newly
formed IgG heavy and light chains were expressed
under the control of the RSV LTR and CMV promoters,
respectively. Initial restriction analysis of library pool
DNA and colony PCR from 38 individual bacterial
colonies indicated 100 % efficiency of pQMCF IgG vector
assembly from the 4 fragments (data not shown). The
Western blot analysis of the culture medium sample from
library pool DNA-transfected CHO85EBNALT cells con-
firmed the predominance of intact rabbit IgG molecules
assembled from the separately expressed heavy and light
chains (Fig. 5b). The analysis of the same library pool
transfection medium sample in mouse CD48 ELISA
demonstrated the presence of antigen-specific antibodies
(Fig. 5c). Finally, the screening of 95 clones in CHO85EB-
NALT cells resulted 39 % of clones with ELISA readouts
15–45 times over negative control and considered as
“positive” (Fig. 5d).
Some positive (H2, A2, B2) and negative (F8, F12)
clones (readouts indicated in Fig. 5d) were selected
for sequencing of heavy and light chain cDNAs. All
sequenced clones had essentially identical VH se-
quence, suggesting that the binding with the antigen
was mainly determined by the VL domain. In this,
the differences between the sequences of positive and
negative clones were observed, most recognizable in
CDR3 region (Fig. 5e). We have been observed that
very high percentage of positive clones in the screen-
ing often associate with the limited number of differ-
ent VH or/and VL sequences that are combined in
the library. It may indicate that only few best binders
have remained associated with the antigen coated sur-
face during the repeated washing steps in B-cell cap-
turing. Alternatively, particular cDNA product among
others (e.g. this one provides most optimal template
for the primer mix during the initial rounds of PCR)
may be preferrably amplified. Irrespective of the
excact mechanism, we have determined that increas-
ing the variability of the recovered MAbs can be
achieved by setting up more capturing reactions. This
is clearly preferable to increasing the cell number per well.
Selective capturing using the pre-adsorption of source cells
We are interested in the development of reagents for
immunoassays usable for the measurement of protein
antigens in different test samples. Thus, there is a need
for MAbs that recognize specific target proteins or even
protein isoforms but not off-target antigens sharing cross-
reactive or even identical epitopes. We have observed that
MAbs retrieved from immunizations with full-length pro-
teins have unacceptable levels of cross-reactivity, and it is
time-consuming to sort out the small number of “right”
MAbs from the total population of recovered antibodies.
Therefore, we have introduced an optional step during
which the source cells are pre-adsorbed with an excessive
amount of off-target antigen(s) prior to capturing with the
desired target. In this way, all binding sites that are cross-
reactive with the non-desired targets can be pre-saturated
and cannot bind to the target antigen anymore. This is
illustrated here by the development of MAbs against hu-
man ribonuclease 8 (R8) protein from spleen cells of an
immunized rabbit. The goal was to obtain anti-R8 MAbs
that have minimal cross-reactivity with the highly hom-
ologous human ribonuclease 7 (R7) (Fig. 6a); thus, a pre-
adsorption step with R7 was included before cell capture.
The R8-immunized rabbit spleen cells were captured in
two ways: by using an R8-coated surface in capture
medium as described in the section “Collection and prep-
aration of spleen cells” above or by supplementing the
medium with R7 protein (100 μg/ml) and including a
short (15 min) pre-adsorption step in suspension before
the cells were centrifuged to R8-coated wells. As illus-
trated in Fig. 6b, the library pool from cells not pre-
adsorbed gave relatively low readouts. Most surprisingly,
the responses were higher for R7 protein, and the readouts
of R8 protein binding were just above background. This
may indicate that dominant antigenic epitopes in the R8
protein exposed in vivo were not equally available to plas-
tic bound antigen in vitro. In contrast, a potent anti-R8
response was detected in the library pool obtained using
pre-adsorption with R7 protein. There was some response
to the R7, but the titer was significantly higher for R8 (Fig.
6c). In two rounds, totally 92 individual clones were ana-
lyzed from both libraries for their binding to R8 and R7
protein, respectively. The results shown in Fig. 6d are in
accordance with data from library pool analyses. The R7-
reactive MAbs with weak readouts were detected in the li-
brary prepared without pre-adsorption (left diagram in
Fig. 6d) but there were more R8-reactive than R7-reacive
clones when the pre-adsorption was used (right diagram
in Fig. 6d). Importantly, only from pre-adsorbed pool we
found the desired MAbs that reacted with R8 and exhib-
ited no or low cross-reactivity with the R7 protein (sur-
rounded with box in Fig. 6d).
We propose that this pre-adsorption step is useful for
screening antibodies from organisms immunized with
complex antigens. For example, using the viral surface
proteins pseudotyped VLPs rather than purified surface
proteins alone for immunization generally gives better
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odds of recovering a virus-neutralizing antibody [30].
Using the same VLPs for capturing antigen-expressing
cells as well as for screening yields opportunities to iso-
late and clone such antibodies. However, using VLPs for
immunization usually results in a mixed response, in-
cluding many MAbs specific to off-targets (e.g., directed
to structural components of the VLPs). Thus, it may be
useful to inhibit the recovery of the off-target antibodies
by pre-adsorption of the antibody-expressing source
cells with non-pseudotyped VLPs.
Production, sequence analysis and applications of the
developed MAbs
We developed the Hybrifree method to address short-
comings in our recombinant antibody isolation and pro-
duction projects. Antibodies developed via screening in
E. coli cells often showed low productivity or loss of
activity after production in mammalian cells. To date,
we have successfully used the HybriFree method for the
isolation of antibody variable domain cDNA from mice,
rabbits and chickens immunized with different viral and
cellular antigens. The sequence information and/or ex-
pression vectors obtained by this method have been used
for the establishment of larger scale transient production
and the purification of scFv-Fc antibodies as well as in-
tact IgG and IgY antibodies in CHO85EBNALT cells.
Sometimes the DNA minipreparations used for screen-
ing can also be applied for immediate transient produc-
tion of the selected antibodies in amounts sufficient for
further characterization. For example, we found interest-
ing MAb against human BDNF using the screening of
IgG molecules (vector shown in Fig. 5a) with rabbit VH
and VL domains fused with human IgG constant re-
gions. Then the plasmid mini-preparation was used for
transfection of serum-free culture of CHO85EBNALT
cells. After 10 days approximately 40 ml of supernatant
Fig. 6 Selective development of non-cross-reactive antibodies using a pre-adsorption step. a Global alignment of the mature protein sequences
of human ribonuclease 8 (R8, UniProt ID: Q8TDE3) and ribonuclease 7 (R7, UniProt ID: Q9H1E1). b ELISA assay result obtained using supernatants
of CHOEBNALT85 cells transfected with 1 μg of library pool DNA derived from splenocytes captured without a pre-adsorption step. c The same
ELISA assay using the library pool from splenocytes captured using the pre-adsorption step with R7 protein (100 μg/ml). d The distribution of
R7-reactive (R7+), R8-reactive and only R8-reactive (R8+/R7-) scFv-Fc clones retrieved from the pre-adsorbed and control libraries, respectively
Kivi et al. BMC Biotechnology  (2016) 16:2 Page 11 of 14
was collected that contained ~100 μg/ml of fully assem-
bled anti-BDNF IgG with specific anti-BDNF activity
confirmed by concentration curve in BDNF ELISA (Fig.
7a). The sequence analysis of developed MAbs has often
revealed limited numbers of unique CDRs (CDR1-3 in
VH and CDR1-3 in VL) that are differentially combined in
the clones derived from a particular animal. For example,
using 93 clones derived from chicken immunized with
HPV18 full-length E2 protein, 7 MAbs identified by our
method using only 1/3 of the of the protein (C-terminal
DNA binding domain) for the B-cell capturing and screen-
ing. The sequence analysis of the MAbs revealed that the
Fig. 7 Production and sequence analysis of the obtained MAbs. a Coomassie staining of the supernatant (10 μl) collected after 10 days culture of
CHOEBNALT85 cells transfected with the anti-BDNF IgG plasmid vector. Heavy and light chains and assembled IgG molecule are indicated in
reduced (DTT+) and non-reduced (DTT-) sample conditions, respectively. Concentration dependent ELISA of the same antibody batch is represented
by the diagram using coating with the BDNF or a non-relevant control protein. b Seven Mabs recognizing the C-terminal DNA binding domain of the
HPV18 E2 protein were derived from immunized chicken. VH and VL protein sequence analysis revealed that their variable domains were formed using
a limited number of CDR sequences. The same color in a particular CDR position (CDR1, 2 or 3 in the VH or VL, respectively) indicates an identical CDR
sequence. The number of identified clones with this particular CDR pattern is shown at left (#). c Variable domain sequences of anti-artemin MAbs
developed by the method from the spleen of immunized mice. The same color code is used as for the ELISA data of the same MAbs shown in the
Fig. 4e and f. CDRs are surrounded by boxes
Fig. 8 a Applications of the HybriFree MAbs. a Anti-human Dnase I IgY antibodies were re-constructed from developed MAb sequences from
chicken. These were produced in CHO cells and can be used for the detection of a ~35 kD hDNase I band by western blot assay (the expression
vector producing non-relevant IgY is used as a negative control). b GP-positive Ebola VLPs MAb derived from a rabbit immunized with Ebola virus
VLPs serves as a sensitive and selective reagent for the visualization of Ebola virus glycoprotein (GP) expression (green) in human cells by
immunofluorescence. Nuclei are counterstained with DAPI (blue). c ELISA assay with 4 anti-GP MAbs (each represented by different color) using
purified GP (filled circles), GP-positive Ebola VLPs (open circles) or GP-negative Ebola VLPs (Xs) as a target
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variable domains of these 7 antibodies were formed using a
limited number of distinct CDR sequences: 1 sequence
variant for VH-CDR3; 2 variants for VH-CDR1, VH-
CDR2, VL-CDR2 and VL-CDR3; and 3 variants for VL-
CDR1 (Fig. 7b). In general, higher variability was observed
for mouse and rabbit antibodies. This is illustrated in Fig. 7c
with variable domain sequences of mouse anti-artemin
MAbs developed by the method (ELISA results are shown
in Fig. 4e and f).
The variety of MAbs developed and characterized by
their recognition of linear epitopes are useful for detection
in assays such as immunoblotting (Fig. 8a) and immu-
nofluorescence (Fig. 8b). These antibodies can also bind
conformational epitopes and have potential applications in
the development of products with biological activity. The
usefulness of very specific MAbs developed by the method
is also illustrated here with rabbit derived scFv-Fc mole-
cules against Ebola virus GP. The reagent specificity is
certainlt the issue for detection of the viral particles sur-
rounded by the envelope derived from the host cell mem-
brane that is studded with GP spikes. In Fig. 8c is shown
of ELISA assay conducted with 4 anti-GP MAbs. Here the
purified GP or GP-positive Ebola VLPs (both prepared in
human 293 cells) was used as the target. Compared to
purified protein (filled circles in Fig. 8c), the detection of
membrane bound GP on the VLP (open circles in Fig. 8c)
resulted in relatively lower but clearly positive readouts.
However, non-specific binding to empty Ebola VLPs
prepared without the GP component (marked by Xs in
Fig. 8c) was not detected even at high concentrations of
scFv-Fcs.
Conclusions
We describe the novel HybriFree method for the devel-
opment of monoclonal antibodies from an animal spe-
cies for which coding sequence information of the
antibody variable domain is available. This robust and
rapid method includes the enrichment of source material
by capturing specific antibody-producing cells for the
construction of a combinatorial VH-VL library screened
after expression in mammalian cells. The resultant expres-
sion vectors can be directly used to establish medium-
scale transient production in mammalian cell factories
without the need for additional cloning steps.
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